Hepatic Encephalopathy

/Tag:Hepatic Encephalopathy

A C”Urea”Ous Case of Post-Partum Hepatic Encephalopathy

Case Presentation: A 30 year old woman with history of benign essential hypertension, hyperlipidemia, gastroesophageal reflux disease and fatty liver disease who was four days post-partum after a vaginal delivery complicated by post-partum depression presented [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Adult, Clinical Vignettes Abstracts|Comments Off on A C”Urea”Ous Case of Post-Partum Hepatic Encephalopathy

A CASE OF RECURRENT HEPATIC ENCEPHALOPATHY: LACTULOSE IS NOT THE ANSWER

Case Presentation: A 51-year-old woman presented with recurrent confusion and altered mental status over the past 6 months. She reported associated hallucinations, altered sleep cycle and hyper-arousal symptoms. She was treated with lactulose and rifaximin [...]

By | 2018-03-19T15:44:08+00:00 March 19th, 2018|Adult, Clinical Vignettes, Uncategorized|Comments Off on A CASE OF RECURRENT HEPATIC ENCEPHALOPATHY: LACTULOSE IS NOT THE ANSWER

ASSESSING CONFUSION: AN INVESTIGATION INTO HEALTHCARE PROVIDERS PERCEPTION OF AMMONIA TESTING.

Background: Hepatic encephalopathy (HE) is a common complication in patients with end stage liver disease. Variability in presentation can be a source of clinical uncertainty for medical providers. Ammonia levels have historically been used to [...]

By | 2019-03-11T14:24:05+00:00 March 11th, 2019|Hospital Medicine 2019, Quality Improvement, Research|Comments Off on ASSESSING CONFUSION: AN INVESTIGATION INTO HEALTHCARE PROVIDERS PERCEPTION OF AMMONIA TESTING.

DON’T ACCUSE THE LIVER: AN ELUSIVE, OCCLUSIVE CASE OF ENCEPHALOPATHY

Case Presentation: A hospitalized 71-year-old female became acutely encephalopathic after an esophagogastroduodenoscopy under conscious sedation which was performed to evaluate a chronic esophageal ulcer and other potential causes of dysphagia. Her past medical history was [...]

By | 2018-03-19T13:06:30+00:00 March 19th, 2018|Adult, Clinical Vignettes, Hospital Medicine 2018|Comments Off on DON’T ACCUSE THE LIVER: AN ELUSIVE, OCCLUSIVE CASE OF ENCEPHALOPATHY

ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

Background: Hepatic encephalopathy (HE) is a common neurological complication in patients with cirrhosis. In addition to numerous morbidity-related issues, HE is associated with substantial economic burden. Treatment includes lactulose or rifaximin, a nonsystemic antibiotic that [...]

By | 2018-03-19T12:52:34+00:00 March 19th, 2018|Hospital Medicine 2018, Research, Value in Hospital Medicine|Comments Off on ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin, a nonsystemic antibiotic, may be used alone or in combination with lactulose for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults. This analysis evaluated rifaximin alone and rifaximin + lactulose [...]

By | 2018-03-19T15:44:00+00:00 March 19th, 2018|Research, Transitions of Care, Uncategorized|Comments Off on PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults and may be used alone or in combination with the cathartic lactulose. This [...]

By | 2019-03-11T14:21:17+00:00 March 11th, 2019|Hospital Medicine 2019, Patient Safety, Research|Comments Off on RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence in adults and may be used in combination with lactulose. Practice guidelines state that rifaximin [...]

By | 2019-03-11T14:25:21+00:00 March 11th, 2019|Hospital Medicine 2019, Research, Transitions of Care|Comments Off on RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS